FDA Approves Oxlumo (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1
The Pharma Data
NOVEMBER 24, 2020
The safety and efficacy of Oxlumo are also being evaluated in the ongoing ILLUMINATE-C Phase 3 clinical trial in patients of all ages with advanced PH1, including patients on dialysis. 0.514 mmol/24 hr/1.73 0.771 mmol/24 hr/1.73 Visit OXLUMO.com for more information, including full Prescribing Information.
52 
Let's personalize your content